Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer
Languages of publication
Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival.
- 1. International Agency for Research on Cancer: GLOBOCAN 2018. http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet. pdf.
- 2. Center MM, Jemal A, Smith RA et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59: 366-78.
- 3. Wilkes GM. Metastatic colorectal cancer: management challenges and opportunities. Oncology. 2011; 25(7): 32-44.
- 4. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treatment Rev. 2015; 41: 777-83.
- 5. Burness CB, Duggan ST. Trifluridine/tipiracil: a review in metastatic colorectal cancer. Drugs. 2016; 76: 1393-402.
- 6. Mayer R, Van Cutsem E, Falcone A et al. RECOURSE Study Group Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909-19.
- 7. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27 (8): 1386-422.
- 8. European Medicines Agency. European public assessment report (EPAR) for Lonsurf. 2016. http://www.ema.europa.eu.
Publication order reference